Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
暂无分享,去创建一个
D. Esseltine | D. Reece | V. Kukreti | G. Merlini | U. Hegenbart | J. Bladé | C. Enny | G. Palladini | V. Sanchorawala | J. Fermand | R. Comenzo | A. Cakana | H. Hassoun | R. Vescio | L. Heffner | L. Pei | H. V. D. van de Velde